Names and pronunciation
(ah-poe-more′feen) Apokyn, Kynmobi, Movapo
PDF page 99
Loading InternPractice…
Drug reference
(ah-poe-more′feen) Apokyn, Kynmobi, Movapo
PDF page 99
Func. class.: Antiparkinson agent
PDF page 99
Chem. class.: DOPamine agonist, non-ergot
PDF page 99
USES: For use as rescue of “off” epi- sodes associated with advanced Parkin- son’s disease
PDF page 99
CONTRAINDICATIONS: Hyper- sensitivity to this product, sulfites, or benzyl alcohol, IV use, major psychotic A disorder; concurrent treatment with drugs of the 5-HT3 antagonist class (e.g., ondansetron, granisetron, alosetron)
PDF page 99
DOSAGE AND ROUTES • Adult: Test dose: SUBCUT 0.2 mL (2 mg) (test dose) where B/P can be closely monitored (before dose and 20, 40, 60 min after); if tolerated and patient responds, then begin with 0.2 mL (2 mg); may in- crease by 1 mg every few days, max 0.6 mL (6 mg) • Usual dosage: SUBCUT 0.3-0.6 mL (3-6 mg), average frequency tid • SL: 10 mg as needed at ≥2 hr for “off episodes” up to a max 5 doses daily
PDF page 99
Available forms: Solution for injection 10 mg/mL with benzyl alcohol See Appendix B
PDF page 99
• Adult: Test dose: SUBCUT 0.2 mL (2 mg) (test dose) where B/P can be closely monitored (before dose and 20, 40, 60 min after); if tolerated and patient responds, then begin with 0.2 mL (2 mg); may in- crease by 1 mg every few days, max 0.6 mL (6 mg)
PDF page 99